STING1 and neoplasm: The application of the cGAS-STING pathway in cancer therapies is complex because it varies in different cancer types, and there are still some challenges in utilization of STING, for example, it can activate the adaptive immune responses by type I IFN production, but it is difficult to control the local level of type I IFNs in tumor cells.